Cromolyn disodium
Based on 11 publication(s) in Google Scholar
Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.98%
- CAS No.: 15826-37-6
- Formule: C23H14Na2O11
- Masse moléculaire:512.33
-
Stockage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-115768
Compound 48/80Mast Cell Activator -
HY-18739
Phorbol 12-myristate 13-acetatePKC Activator -
HY-B0713
AmlexanoxIKK Inhibitor -
HY-113914
9-ING-41GSK-3β Inhibitor -
HY-B0320AR
Cromolyn disodium (Standard)Standard of Cromolyn disodium -
HY-130592
Compound 48/80 trihydrochlorideHistamine Releaser/Mast Cell Degranulator -
HY-N0005
Curcuminp300 Histone Acetylatransferase Inhibitor -
HY-59090
1-AzakenpaulloneGSK-3 Inhibitor -
HY-B0157
KetotifenHistamine 1 Receptor Blocker -
HY-B0166
L-Ascorbic acidAntioxidant -
HY-N0156
Oleanolic acidAutophagy Inducer -
HY-Y0873
PEG300Neutral Polymer
Publications Citing Use of MedChemExpress (MCE) Cromolyn disodium
More- Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]
- Nat Commun. 2025 Jan 8;16(1):509. [Abstract]
- Pharmacol Res. 2017 Nov;125(Pt B):150-160. [Abstract]
- J Med Chem. 2021 Oct 14;64(19):14344-14357. [Abstract]
- J Invest Dermatol. 2025 Nov 4:S0022-202X(25)03517-1. [Abstract]
- Int J Mol Sci. 2026 Apr 2;27(7):3226. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114880. [Abstract]
- Int J Mol Sci. 2025 Feb 14;26(4):1619. [Abstract]
- J Inflamm Res. 2026 May 11:19:577472. [Abstract]
- Mol Biol Rep. 2026 Apr 7;53(1):589. [Abstract]
- Res Sq. 2025 Apr 08.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
IHC
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.986 μM
Compound: 2
|
Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
|
[PMID: 23713606] |
| CHO | EC50 |
1.26 μM
Compound: 2
|
Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
|
[PMID: 23713606] |
| CHO | EC50 |
4.84 μM
Compound: 2
|
Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
|
[PMID: 23713606] |
| LAD2 | IC50 |
>1 mM
Compound: DSCG
|
Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay
Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay
|
[PMID: 23617679] |
| Mast cell | ED50 |
2.55 μg/mL
Compound: disodium cromoglycate
|
Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay
Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay
|
[PMID: 82617] |
| Mast cell | IC50 |
3 μM
Compound: 130; DSCG
|
Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC)
Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC)
|
[PMID: 34998058] |
| Mast cell | IC50 |
6.5 μM
Compound: cromolyn sodium
|
Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins
Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins
|
[PMID: 88523] |
| RBL-2H3 | IC50 |
1540 μM
Compound: DSCG
|
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
|
[PMID: 14510616] |
In Vitro
Cromolyn (0-100 μM; 3-10 min) disodium can inhibit IgE- and antigen-induced degranulation and PGD2 synthesis in rat peritoneal mast cells[1].
Cromolyn (0-100 μM; 0-72 h) disodium can block S100P-promoted cell proliferation, invasion, and increased NF-κB activity in Panc-1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cromolyn (5 mg/kg; intraperitoneal injection; 5 weeks) disodium has anti-tumor activity in a mouse model of pancreatic cancer[2].
Cromolyn (6.3 mg/kg; intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia) disodium has an ameliorative effect in a model of amyotrophic lateral sclerosis[3].
Cromolyn (1-3.15 mg/kg; intraperitoneal injection; 3 times a week; 12 weeks) disodium has a neuroprotective effect in a mouse model of Alzheimer's disease[4].
Cromolyn (1.43-5.72 mg/kg; intraperitoneal injection; 1 month) disodium has a hypoglycemic effect in mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CB17 scid mice aged 4 weeks old treated BxPC-3 and MPanc-96 cells[2]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; 5 weeks
-
Result:Significantly reduced tumor burden.
Reduced lung metastasis in the BxPC-3 model and both liver and lung metastases in the MPanc-96 model.
Had no effect on body weight.
-
Animal Model:SOD1G93A mice[3]
-
Dosage:6.3 mg/kg
-
Administration:Intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia
-
Result:Delays disease onset.
Improved motor deficits in the PaGE task.
Increased survival of lumbar spinal cord motor neurons, decreased denervation at the neuromuscular junction.
Reduced pro-inflammatory cytokine and chemokine levels in the spinal cord and plasma.
Decreased mast cell degranulation in the tibialis anterior muscle.
-
Animal Model:APPSwedish expressing Tg2576 mice[4]
-
Dosage:1 and 3.15 mg/kg
-
Administration:Intraperitoneal injection; 3 times a week; 12 weeks
-
Result:Reduced the levels of Aβ40 and Aβ42 in brain TBS-insoluble fractions.
Increased the level of Aβ38.
Promoted the phagocytosis of β-amyloid by microglia.
-
Animal Model:Normal Balb/c mice, chronic type II diabetic Balb/c mice, and chronic obese Balb/c mice[5]
-
Dosage:1.43, 2.86 and 5.72 mg/kg
-
Administration:Intraperitoneal injection; 1 month
-
Result:Dose-dependently reducted blood glucose, body weight, and resistin levels.
Increased liver glycogen, insulin, C-peptide, and adiponectin levels in mice.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 15826-37-6
-
Appearance Solid
-
Masse moléculaire 512.33
-
Formule C23H14Na2O11
-
Color White to off-white
-
SMILES
OC(COC1=C2C(C=C(C(O[Na])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O[Na])=O)OC4=CC=C3)=O
-
Synonyms
Cromoglycate disodium; Cromoglicic acid disodium; FPL-670
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. [Abstract]2025 Mar 10;43(3):446-463.e7. PMID: 39919737
Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]
Cromolyn disodium (DSCG: 10 mg/kg). Experimental workflow and tumor growth of the murine 4T1 breast tumor model. Data on day 15 were presented.
Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]
Cromolyn disodium (DSCG: 10 mg/kg). GSVA scores of immune cell subsets after different treatments in the murine 4T1 breast tumor model.
-
Nat Commun
S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism. [Abstract]2025 Jan 8;16(1):509. PMID: 39779666
Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):509. [Abstract]
Cell viability of HT1080 S100P OE cells pretreated with indicated concentrations of Cromolyn disodium for 12 h and then treated with RSL3 (200 nM) for 6 h.
-
Pharmacol Res
Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-κB signaling. [Abstract]2017 Nov;125(Pt B):150-160. PMID: 28867637
Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2017 Nov;125(Pt B):150-160. [Abstract]
The IL-33 production in different treatment groups is determined in rat skin by immunohistochemistry assay.
-
J Med Chem
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]2021 Oct 14;64(19):14344-14357. PMID: 34547896 -
J Invest Dermatol
MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release. [Abstract]2025 Nov 4:S0022-202X(25)03517-1. PMID: 41197765 -
Int J Mol Sci
Bile Canalicular Bitter Taste Receptors Inhibit β-Adrenergic Receptor-Induced Lipolysis in Steatotic Hepatocytes. [Abstract]2026 Apr 2;27(7):3226. PMID: 41977407 -
Int Immunopharmacol
Edaravone attenuates cerebral inflammation by inhibiting mast cells degranulation via ROS/STIM1 signaling pathway in HIE model. [Abstract]2025 Jun 26:159:114880. PMID: 40394799 -
Int J Mol Sci
2025 Feb 14;26(4):1619. PMID: 40004083 -
J Inflamm Res
Astragalus membranaceus and Salvia miltiorrhiza Inhibit Tryptase/PAR2-Mediated Mast Cells - Peritoneal Mesothelial Cells Crosstalk to Ameliorate Peritoneal Fibrosis. [Abstract]2026 May 11:19:577472. PMID: 42147796 -
Mol Biol Rep
Disodium cromoglycate restricts human tau hyperphosphorylation and manifestation of associated phenotypes by inhibiting GSK3β activity in Drosophila disease models. [Abstract]2026 Apr 7;53(1):589. PMID: 41945164 -
Solvant et solubilité
In Vitro:
H2O : 50 mg/mL (97.59 mM; Need ultrasonic)
DMSO : 25 mg/mL (48.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (97.59 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Oka T, et al. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest. 2012 Oct;92(10):1472-82. [Content Brief]
[2]. Arumugam T, et al. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. [Content Brief]
[3]. Granucci EJ, et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. [Content Brief]
[4]. Zhang C, et al. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8(1):1144. [Content Brief]
[5]. Motawi TM, et al. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013 Sep;27(9):425-36. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.9519 mL | 9.7593 mL | 19.5187 mL | 48.7967 mL |
| 5 mM | 0.3904 mL | 1.9519 mL | 3.9037 mL | 9.7593 mL | |
| 10 mM | 0.1952 mL | 0.9759 mL | 1.9519 mL | 4.8797 mL | |
| 15 mM | 0.1301 mL | 0.6506 mL | 1.3012 mL | 3.2531 mL | |
| 20 mM | 0.0976 mL | 0.4880 mL | 0.9759 mL | 2.4398 mL | |
| 25 mM | 0.0781 mL | 0.3904 mL | 0.7807 mL | 1.9519 mL | |
| 30 mM | 0.0651 mL | 0.3253 mL | 0.6506 mL | 1.6266 mL | |
| 40 mM | 0.0488 mL | 0.2440 mL | 0.4880 mL | 1.2199 mL | |
| H2O | 50 mM | 0.0390 mL | 0.1952 mL | 0.3904 mL | 0.9759 mL |
| 60 mM | 0.0325 mL | 0.1627 mL | 0.3253 mL | 0.8133 mL | |
| 80 mM | 0.0244 mL | 0.1220 mL | 0.2440 mL | 0.6100 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cromolyn disodium Related Classifications
HY-B0320A Related Classifications
Powered by Bioz